tbuckley/cabot-search huggingface dataset:
美蓝染色在腱鞘囊肿切除术中的应用
Authors: 罗小庆, 吴锦昌, 张绍海, 唐秋华, 吴炳生, 周如英
Journal: BMJ (2010)

腱鞘囊肿在临床上多见,治疗方法有囊肿压破、注射硬化剂或激素、抽吸、皮下刺破、囊肿切除等.各种方法都有较高的复发率,杜娟和魏艳霞[1]报道手术切除复发率为4.7%,吴锦昌[2]将美蓝染色技术应用于腕背腱鞘囊肿切除术中,随访1～5年未见复发.本研究2005年1月至2008年6月在腱鞘囊肿切除术中运用改良美蓝染色技术57例,使囊壁染色更方便、快捷,且美蓝液不易渗漏而致周围组织染色,获得了较好的效果。
Prediction and prognostic validation of colorectal cancer therapeutic effect of WM-S1-030 using pre-clinical CTC animal model.
Authors: Hae Ung Lee, Jai-Hee Moon, Joseph Kim, Seong Keun Kim, Jae Sik Shin, Young Jin Choi, Seung-Woo Hong, Sung Min Kim, Hyun Ho Lee, Jae-Chan Park, Dong-Hoon Jin, Byung Hee Jeon
Journal: Journal of Clinical Oncology (2020)

e15557 Background: CTC (Circulating tumor cells) has the advantage of being able to effectively investigate non-invasive diagnosis, prediction, and prognosis for non-surgical carcinoma or tissue sample collection. We have developed WM-S1-030 (WMBIO) as a novel inhibitor for mtRTK (mutant receptor tyrosine kinase) identified important targets for cancer progression and metastasis in various cancers, including colorectal cancer, and have tried to prove the possibility of CTC diagnosis, prediction and prognosis of WM-S1-030 using tumor animal models. Methods: Six of colon cancer cell lines expressing mtRTK (pTyr-mtRTK) were transplanted into Balb.c nude mice and NSG mice to collect peripheral blood when the tumor size reached 1000 mm 3 . CTCs were quantified in peripheral blood using the Smart Biopsy cell isolator (Cytogen). The expression of pTyr-mtRTK in CTCs was analyzed via the Smart Biopsy Image Analyzer (Cytogen). Colon cancer cell lines expressing pTyr-mtRTK were transplanted into NSG mice and we examined the tumor suppression, the enumeration of CTCs and pTyr-mtRTK expression in CTCs after administration of WM-S1-030. We also identified CTCs in peripheral blood of colon cancer patients and analyzed expression of pTyr-mtRTK in CTCs through Smart Biopsy system. Results: As results of the enumeration of CTCs after tumor transplantation into Balb.c nude mice and NSG mice, the number of CTC was 8 ~ 20 times higher peripheral blood in the NSG model, which indicates innate immune responses are critical for the survival of CTCs. Half of CTCs isolated from the blood expressed pTyr-mtRTK. The tumor size, the number of CTCs, and the expression of pTyr-mtRTK in CTCs were examined after the administration of WM-S1-030. The volume of tumor decreased by 67% in the WM-S1-030 group compared to the vehicle. The number of CTCs was reduced by approximately three times after the treatment of WM-S1-030 and also the number of CTCs expressing pTyr-mtRTK was significantly decreased. CTC detection and pTyr-mtRTK expression analysis in the peripheral blood of colon cancer patients detected 9 CTCs per 10 ml of peripheral blood, of which 11 % of CTCs representing pTyr-mtRTK were confirmed. Conclusions: WM-S1-030 was developed and confirmed in the CTC-based animal model, which implies that the analysis of CTCs is the powerful tool for predicting/ prognosing WM-S1-030 in the pre-clinical analysis. Currently, we are conducting clinical diagnostic validation using CTC in the blood of colorectal cancer patients and preparing for clinical trial of WM-S1-030.
Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).
Authors: Jane Goodall, Zoe June Assaf, Zhen Shi, George Seed, Liangxuan Zhang, Ben Lauffer, Wei Yuan, Matthew Wongchenko, Flavia Oliveira, Suzanne Carreira, Steven Gendreau, Johann S. De Bono
Journal: Journal of Clinical Oncology (2020)

5508 Background: ctDNA can inform on prognosis, treatment response and survival. We evaluated ctDNA in serial plasma samples from patients enrolled in A.MARTIN (NCT01485861), a randomized phase II study of abiraterone with or without ipatasertib in patients with mCRPC. Methods: Blood was collected in cell-free DNA Streck tubes from 216 patients at 3 time points; baseline, C3D1 and end of treatment. Cell-free DNA (cfDNA) was extracted from plasma using a Circulating DNA Kit (Qiagen) on a QIASymphony machine (Qiagen). 25ng of extracted cfDNA was used in library preparation, constructed with a custom designed, 58 gene, QIAseq Targeted DNA panel (Qiagen) enriched for PI3K/AR pathway genes. Samples were sequenced to mean depth of 3394x on a NextSeq500 machine. Unless otherwise noted, all analyses combine patients across the 3 study arms, and reported p-values are unadjusted. Results: Baseline (BL) ctDNA positivity correlated with radiological progression-free survival (rPFS; HR: 1.8 [95% CI 1.3-2.6], p &lt; 0.01); this association with rPFS was maintained in a multivariate cox model with &gt; 5 baseline clinical variables (HR: 1.6 [95% CI 1.1-2.4]; p = 0.011). Patients with a C3D1 reduction in ctDNA had superior rPFS compared to patients with a C3D1 increase in ctDNA (HR: 2 [95% CI 1.3-3.2], p &lt; 0.01). The rate of ctDNA clearance at C3D1 was higher in the Ipatasertib 400mg arm compared to placebo (56.3% versus 24.4%, p &lt; 0.01). We find that changes in ctDNA associated with best confirmed overall response (p = 0.024); CR patients had the greatest reduction in ctDNA (mean of -23.4%), followed by PR (-16.3%), then SD (-4.1%), and lastly PD patients (-1.3%). Changes in ctDNA levels correlated with SLD changes (rs = 0.289, p = 0.05), and also PSA changes (rs = 0.33, p &lt; 0.01). Changes in ctDNA were associated with rPFS in a multivariate cox analysis that included PSA change (p &lt; 0.01), as well as in a separate multivariate analysis that included SLD change (p &lt; 0.01). Lastly, we explored CNVs and observed emerging resistance mutations in progression samples, including alterations in TP53, AR, FOXA, PTEN, and PI3K/AKT pathway genes. Conclusions: ctDNA analyses may help (i) identify poorer prognosis disease at baseline, (ii) inform on treatment response (CR/PR/SD/PD) and radiological progression free survival (rPFS) in on-treatment (C3D1) samples, and (iii) can elucidate emerging resistance mechanisms at disease progression. Clinical trial information: NCT01485861 .
INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Authors: Aaron Richard Hansen, Thomas S. Stanton, Min Hee Hong, Ezra E.W. Cohen, Hisham Mohamed Mehanna, Michael Jon Chisamore, David Turner, Sapna Yadavilli, Kelly Bell, Carlos Baccan, Rosalida Leone, Helen Chen, Helen Zhou, Catherine Elizabeth Ellis, Marc S. Ballas, Axel Hoos, Danny Rischin
Journal: Journal of Clinical Oncology (2020)

TPS6591 Background: Pembrolizumab as part of first-line treatment for patients (pts) with R/M HNSCC has improved survival. However, in order to further improve outcomes in this population investigation of rational combinations targeting different mechanisms that cancers exploit to evade the immune system is required. ICOS, a member of the CD28/B7 immunoglobulin receptor superfamily, provides a co-stimulatory signal augmenting T-cell proliferation, cytokine production, cytotoxic function and survival. GSK609 is a humanized IgG4 antibody selected for its potent agonist activity and non-depleting properties. The rationale for targeting ICOS with GSK609 plus PD-1 blockade with PE is supported by preclinical and clinical evidence (Rischin, et al. Annals of Oncol 2019;30[Supplement_5]:v454–5). INDUCE-3 trial (NCT04128696) will explore if the addition of GSK609 to PE improves outcomes of pts with R/M HNSCC. Methods: INDUCE-3 uses a 2-in-1 adaptive design that has the option to seamlessly expand from an initial Phase 2 to a Phase 3 study. Pts (n = 600) will be stratified by PD-L1 status and HPV status (oropharynx only) then randomly assigned in a 1:1 ratio to receive GSK609 plus PE or PL plus PE, every 3 weeks until progression, unacceptable toxicity, or up to 35 cycles. GSK609 plus PE will be assessed for superiority versus PL plus PE in overall survival (OS) and progression-free survival (PFS) per RECISTv1.1 as dual primary endpoints; secondary endpoints include PFS per immune-based RECIST; milestone OS; safety and tolerability; time to deterioration in patient-reported physical function and pain. Efficacy and patient-reported outcome endpoints will be assessed in the PD-L1 combined positive score (CPS) ≥1 and ≥20 populations. Key eligibility criteria are aged ≥18 years; locally incurable R/M HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx; no prior systemic therapy in the R/M setting; PD-L1 CPS ≥1 by central testing; measurable disease per RECIST v1.1 and ECOG PS 0/1. Recruitment is ongoing in countries across the globe. Funding: Study is funded by GlaxoSmithKline and in collaboration with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA. Clinical trial information: NCT04128696 .
Computerized features of spatial interplay of tumor-infiltrating lymphocytes predict disease recurrence in p16+ oropharyngeal squamous cell carcinoma: A multisite validation study.
Authors: Germán Corredor, Cheng Lu, Can Koyuncu, Kaustav Bera, Paula Toro, Pingfu Fu, Shlomo A. Koyfman, Deborah Chute, David J. Adelstein, Wade Thorstad, Justin A. Bishop, Farhoud Faraji, James Lewis, Anant Madabhushi
Journal: Journal of Clinical Oncology (2020)

6559 Background: While overall, patients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) have a favorable prognosis, subsets of patients experience disease recurrence (DR) and death despite aggressive multimodality treatment. Aside from routine staging criteria, there are no biomarkers of tumor behavior routinely employed in OPSCC to identify patients at higher risk of DR. In this study we sought to evaluate whether the interplay between tumor-infiltrating lymphocytes (TILs) &amp; cancer cells, in both stromal and epithelial compartments from digitized H&amp;E-stained slides, can predict DR in OPSCC patients. Methods: OPSCC resected specimens from 354 patients (66 with DR) were retrospectively collected from 3 different sites. 107 (16 DR) patients from site 1 formed the training set and 247 (50 DR) patients from sites 2 &amp; 3 formed the independent validation cohort. Computerized algorithms automatically identified 4 types of nuclei (TILs &amp; non-TILs in both stromal &amp; epithelial regions), defined clusters for each nuclei type based on cell proximity, and used network graph concepts to capture measurements relating to the arrangement of these clusters. The top 10 features determined by a statistical selection method (LASSO) were used to train a Cox regression model that assigns a risk of DR to each patient on the training set. The median risk score was used as threshold for stratifying patients on the validation set into low and high-risk of DR. Survival analysis was used to evaluate the stratification given by the trained model. Results: Patients identified by the TIL interplay model as high risk for DR had statistically worse disease specific survival. Univariate analysis yielded an HR=2.49 (95% CI: 1.22-5.07, p=0.04) for site 2 and HR=3.62 (95% CI: 1.39-9.43, p=0.03) for site 3. Multivariate analysis controlling the effect of different clinical variables is shown in the attached table. Conclusions: We introduce a prognostic model based on the automated quantification of the interplay between tumor microenvironment cells that is able to help distinguish OPSCC patients with higher DR risk from those who will experience longer disease-free survival. [Table: see text]
Abstract 3649: Allelic imbalance in <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia
Authors: Byunggil Yoo, Midhat S. Farooqi, Rumen Kostadinov, Warren Cheung, Emily Farrow, Shannon Kelley, Neil Miller, Bing Ge, Margaret Gibson, Patrick Brown, Erin M. Guest, Tomi Pastinen
Journal: Cancer Research (2019)

Abstract Background Infant acute lymphoblastic leukemia (ALL) is a malignant disorder with poor clinical outcome. It is well-known that infant ALL cases with rearrangement of the KMT2A gene (KMT2A-r) have an even poorer prognosis than non-KMT2A-r cases. Interestingly, KMT2A-r infant ALL cases have remarkably few other genetic alterations. We hypothesized that non-coding events in cancer genomes (e.g. loss of expression or methylation) may play a role in this disease. Such events can be captured using genomic analyses in haploid genomes using analytical approaches for allelic imbalance quantification. Here, we examine whether allelic imbalance is a feature of infant ALL. Methods We performed whole genome sequencing (WGS) and RNA sequencing on peripheral blood or bone marrow specimens from 29 KMT2A-r cases and 14 non-KMT2A-r cases at diagnosis (DX), remission (MD), and relapse (RL) as applicable. WGS data from MD samples was phased using a 1000 Genomes reference panel. Biallelic expression was measured on the phased genome for transcripts with at least 2 SNPs and at least 15 aligned reads. Lesser allele fraction (LAF; allele fraction for the less prevalent allele) for DX/RL versus MD samples was compared for transcripts that had LAFs available in at least 3 cases using t-test. Transcript-level p-values were aggregated at the gene level using the Sidak method. Results Allelic imbalance in expression (LAF &amp;lt;= 0.2) was observed in an average of about 600 genes per sample in infant ALL regardless of timepoint. Disease-specific allelic imbalance (skewed in DX samples but not in paired MD samples) was detected in 431 genes for the KMT2A-r cohort and 77 genes for the non-KMT2A-r cohort. A total of 38 genes with allelic imbalance were shared between the two cohorts. Notably, KMT2A was observed to be imbalanced in KMT2A-r samples. Genes of known significance that were found to be skewed included HOXA9 and PARP8. Discussion Our study suggests that allelic imbalance quantification may help uncover novel molecular mechanisms in infant ALL, especially KMT2A-r cases. However, similar to gene expression, the patterns of allelic imbalance in KMT2A-r cases at DX do not allow efficient prediction of which patients go on to relapse. Citation Format: Byunggil Yoo, Midhat S. Farooqi, Rumen Kostadinov, Warren Cheung, Emily Farrow, Shannon Kelley, Neil Miller, Bing Ge, Margaret Gibson, Patrick Brown, Erin M. Guest, Tomi Pastinen. Allelic imbalance in KMT2A-rearranged infant acute lymphoblastic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3649.
Evaluation of emergency department visits in patients treated with immune checkpoint inhibitors.
Authors: Deniz Can Guven, Taha Koray Sahin, Seren Aksun, Hakan Taban, Oktay Halit Aktepe, Nalan metin Aksu, Meltem Akkas, Mustafa Erman, Saadettin Kilickap, Omer Dizdar, Sercan Aksoy
Journal: Journal of Clinical Oncology (2020)

e24160 Background: Immune checkpoint inhibitors (ICIs) are the main drugs for immunotherapy. Their efficacy comes at the expense of adverse events including immune-related adverse events (IRAEs). The emergency department (ED) is an important encounter point in the cancer care. However, the data on the causes of ED visits is scarce. Therefore, we evaluated the ED visits of patients treated with ICIs and tried to determine the predisposing factors. Methods: We performed a retrospective review of adult cancer patients treated with ICIs for any cancer type between 09/2014 and 06/2019 in Hacettepe University Cancer Center. The data about ED visits after the first dose of ICIs to six months after the last dose of ICIs was collected from the hospital registries. Baseline characteristics, stages and types of patients’ tumors, types of ICI, causes for emergency visits and hospital admissions were recorded. Results: A total of 221 patients were included. The median age was 60.7 years (18-86) and 65.6% of patients were males. Median follow-up was 9 months (0.2-55). Nivolumab was the most common immunotherapy (67.9%). Melanoma was the most common diagnosis (27.6%) followed by kidney and lung cancer. 90% of patients had advanced disease and more than half of patients were treated with two or more lines of therapy. The 83 patients (37.6%) had at least one emergency department (ED) visit. Half of these visits resulted in hospital admissions. Thirty-eight patients had more than one ED visits with 14 patients having three or more ED visits. Immune-related adverse events comprised less than 10% of the ED visits with most of the ED visits were related to symptoms attributable to disease burden itself. The median time to ED visit after the first dose of ICI was 126 days. While baseline ECOG status, age, polypharmacy (defined as the regular use of five or more drugs), concomitant chemotherapy, eosinophilia and lactate dehydrogenase levels didn’t significantly increase the risk, patients with regular opioid use and baseline neutrophilia ( &gt; 8000) had a statistically significant risk of ED visits (p values 0.001 and 0.19 respectively). These two factors remained significant in the multivariate analyses. Conclusions: In this study, almost 40% of ICI treated patients had ED visits. Recognition and addressing of this patient group’s problems in the ED is very important as evidenced by ability to discharging half of patients from the ED. Collaboration between the other specialists like emergency medicine specialists is vital for improving the care of patients treated with immunotherapy.
Hypoglycemic drug adjustment and other factors related to reaching target glucose in type 2 diabetic patients under community management: Beijing Community Diabetes Study 9
Authors: Lu Liu, Han-jing Fu, Shen-yuan Yuan, Gang Wan, Liang-xiang Zhu, Ming-xia Yuan, Guang-ran Yang, Su-fang Pan, Xiang-lei Bu, Jian-dong Zhang, Xue-ping Du, Yu-ling Li, Yu Ji, Xiao-ning Gu, Yue Li, Xue-li Cui, Wei Bai, Yu-jie Chen, Zi-ming Wang, Qing-sheng Zhu, Ying Gao, De-yuan Liu
Journal: BMJ (2013)

Objective
To analyze the impact of antidiabetic drugs adjustment and other related factors on reaching target glucose in type 2 diabetic patients under community management.


Methods
Total 3201 patients with type 2 diabetes from 15 community health service centers in Beijing were enrolled in the study, who entered the community diabeta management program from August 2008 to July 2011. According to the glucose-lowering drugs adjustment during 3 years intervention period, patients were divided into 4 groups: 255 patients (8.0%) in insulin-added group, 641 (20.0%) in oral hypoglycemic drugs-added(OHA)group, 1621 (50.6%) in hypoglycemic drug-constant group and 684 (21.4%) in drug-reduced group.


Results
The hemoglobin A1c(HbA1c) levels were reduced from(8.3±1.9)%, (7.4±1.7)%, (6.8±1.3)% and(7.2±1.5)% to (7.5±1.5)% (t=5.38, P 0.05), respectively in above 4 groups after 3 years management; the rates of HbA1c-reduction>0.5% unit were 52.2%(133/255), 34.3%(220/641), 24.6%(399/1621) and 31.9%(218/684), respectively. In 562(43.9%)out of 1280 cases whose HbA1c≥7% before entering the management program, the HbA1c levels reached to <7.0%(P<0.01); the rate of reaching recommended target of HbA1c(48.4%) was significantly higher in OHA group than that of other 3 groups. After 3 years management the blood glucose control rates in patients with low, middle and high educational backgrounds were 61.5%(342/556), 64.7% (1174/1814)and 74.5%(619/813); those in patients with low, middle and high economic levels were 58.1%(971/1670), 77.3%(828/1071) and 66.8%(137/205), respectively(P<0.01). Multivariant logistic regression analysis showed that adding insulin, adding OHA, per capita income ￥2000-4000/M, BMI reduction during management period and age of patients were independent related factors for decrease in HbA1c, with odds ratio (OR) of 0.45, 0.80, 0.72, 0.96 and 1.08(P<0.05).


Conclusion
By management of hypoglycemic drugs actively, patients with type 2 diabetes in Beijing communities show significant improvement in HbA1c levels from 2008 to 2011, but the low educational back ground and low-income groups still should be the primary focus.


Key words: 
Community health services; Diabetes mellitus, type 2; Glycosylated hemoglobin; Antidiabetic agents
S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.
Authors: Sapna Pradyuman Patel, Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth Iannotti Buchbinder, Vernon K. Sondak, Michael C. Lowe, Danae Campos, Elad Sharon, Larissa A. Korde, William Edgar Carson, Antoni Ribas, Kenneth F. Grossmann
Journal: Journal of Clinical Oncology (2020)

TPS10090 Background: Although long term outcomes for most patients with early-stage melanoma is excellent following surgery, patients who have high-risk features such as lymph node involvement have poorer outcomes. Adjuvant therapy (AT) is currently considered for patients with stage III melanoma and selected patients with resected stage IV melanoma. Currently, AT for melanoma is anti-PD-1 or targeted therapy in the presence of a BRAF mutation. At this time we are not able to predict which patients will derive benefit from AT and experience cure. While curative surgery is the goal of early treatment of primary melanoma, some cases with bulky nodal involvement are at high risk of local or distant recurrence despite upfront surgery. Neoadjuvant treatment (NAT) offers the benefit of an early on-treatment pathological sample that can be profiled for biomarkers and correlated with survival. Treating with anti-PD1 while tumor transiently remains in the body may generate a stronger immune response from tumor-infiltrating lymphocytes against in vivo tumor antigens compared to the traditional adjuvant setting where antigen is presented by microscopic residual tumor burden. Pilot studies using NAT with have been initiated in melanoma. Multidisciplinary coordination in these cases is paramount. In these studies, an improvement in relapse-free survival and overall survival has been observed; additionally, pathologic response rates to NAT have been estimated in small studies. Methods: S1801 is a randomized phase II study of AT versus NAT with PEM (NCT03698019). Patients with measurable, clinically detectable and resectable cutaneous, acral, and mucosal melanomas without brain metastasis are eligible. Patients are randomized 1:1 to the AT or the NAT. Patients getting AT receive surgery first followed by 18 doses of PEM 200 mg IV every 3 weeks. Patients getting NAT receive 3 doses of pre-operative PEM followed by surgery and then 15 doses of adjuvant PEM. Radiation may be given on either arm after surgery, at the investigator’s discretion. Primary endpoint is event-free survival measured from the date of randomization to the date of first documented progression that renders the patient unable to receive planned protocol surgery, failure to begin AT within 84 days of surgery, relapse after surgery, or death due to any cause. Safety monitoring is conducted with disease progression and toxicity thresholds. The key Translational Medicine objective of this trial is to determine the pathologic response rate to NAT with 3 doses of PEM. Enrollment is at 94 of a planned 500 patients. Clinical trial information: NCT03698019.
北京市社区超声专业培训考核情况与展望
Authors: 孙心平, 李建国, 蒋保季, 闻胜芝
Journal: BMJ (2009)

目前社区的医疗水平如何?能不能承担好政府给予的任务?从对北京市社区超声专业的培训与考核情况看,不容乐观. 超声检查因其简便、实用、有效、费用低等优点,在临床工作中应用范围非常广泛,对一些常见病、多发病,如脂肪肝、肝囊肿、肝血管瘤、胆结石、胆囊息肉、肾结石、肾囊肿、子宫肌瘤等具有诊断价值.目前,超声检查也是体检项目,在各大医院内完成.若把这项检查放在社区卫生机构,一方面可以使超声检查的受益者数量明显增多,另一方面将大大缩短受检者的就诊时间,提高效率。
支气管哮喘患者需要家庭医疗
Authors: 张玉金
Journal: BMJ (2004)

哮喘是一个反复发作、严重影响患者健康的慢性呼吸系统疾病,这些患者的病情可能较长期地处于比较稳定缓解期,即使急性发作,也属间歇短暂或中度病情,所以多数情况需要在家自我治疗.这就需要规范的家庭医疗来达到最好的治疗效果,其长远目标是最大限度减少哮喘急性发作,夜间无症状,以最低限度剂量的药物控制症状和最少的不良反应,预防发展为不可逆的气道阻塞,使肺功能接近正常水平,能正常参与工作、学习,提高生活质量,延长患者寿命。
激素替代治疗对绝经期糖尿病妇女的影响
Authors: 梁志忠, 黄克坚, 陈幼萍, 邝慧薇, 汤耀斌
Journal: BMJ (2004)

将56例已处于绝经期的糖尿病妇女随机分为两组,试验组给予倍美安(结合型雌孕激素)治疗,对照组给予安慰剂,连续治疗半年.激素替代治疗后糖尿病妇女的血糖、糖化血红蛋白和甘油三酯、胆固醇等均明显下降.说明绝经期糖尿病妇女可能更适合激素治疗。